Cder neurodevelopmental and mental health outcomes in preterm infants: effects of EXP
Ended Definitive Contract Awarded Last action
- Contract number
- 75F40124C00081
- Awardee
-
The Trustees Of Columbia University In The City Of New York UEI QHF5ZZ114M72
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $237,268
Award facts
- Opportunity
-
- FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Pre-Solicitation · FDABAA2400123 · Posted Oct 2, 2023
- Contract value 100% obligated
- $237,268.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10032, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$813,042 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,050,310 |
About this award
The Food and Drug Administration awarded a $237,268 definitive contract to The Trustees of Columbia University in the City of New York on September 16, 2024, for a neurodevelopmental and mental health outcomes study in preterm infants exposed to opioid analgesic, anesthetic, and sedative agents.
The originating solicitation was a Broad Agency Announcement posted October 2, 2023, soliciting advanced research and development proposals to support FDA regulatory science across modernizing product development and evaluation, strengthening post-market surveillance and labeling, and enhancing public health preparedness and response. The contract covers a retrospective cohort study examining neurodevelopmental and mental health outcomes in preterm infants, using electronic health record data from Columbia University's Medical Center, Boston Children's Hospital, and Kaiser Permanente Northern California. The work includes data extraction, analysis of drug-exposure profiles, and stakeholder consensus activities to inform future study design and drug safety evaluation.
Place of performance is New York, NY. The ultimate completion date is March 7, 2025. Performance is firm fixed-price with no set-aside. Boston Children's Hospital and Kaiser Foundation Research Institute (Kaiser Permanente Northern California) are subcontractors contributing retrospective cohort data and supporting data analysis and outcomes evaluation across their respective patient populations.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| The Children's Hospital Corporation | $225,162 | |
| Kaiser Foundation Hospitals | $70,097 |
Quick answers
Who was awarded contract 75F40124C00081?
75F40124C00081 was awarded to The Trustees Of Columbia University In The City Of New York by Food and Drug Administration (Department of Health and Human Services) on September 16, 2024.
How much is contract 75F40124C00081 worth?
The government has obligated $237,268 on 75F40124C00081.
Was contract 75F40124C00081 competed?
The extent of competition for 75F40124C00081 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award